IMNM

Conviction 77HealthcareScan · Thu, Sep 24, 2026

Immunome Inc. (IMNM) closed at $22.35 (-7.80%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 35, RS Rating 96, -25.1% from its 52-week high, +7.3% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

IMNM$22.35-7.80%

ResistanceSupportVol 14Insider buyInsider sell

Vol MA14 1.48M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Immunome Inc.PHARMACEUTICAL PREPARATIONSwww.immunome.com ↗

Price22.35

Change-7.80%

Gap-0.23%

Rel volume3.95×

Avg volume1.3M

Avg $ vol32.19M

SMA 2025.60

SMA 5025.38

SMA 20022.72

Price vs 50-11.93%

Price vs 200-1.62%

MA stackmixed

50/200 cross—

Supertrenddown · 27.13

RSI (14)35

MACD hist-0.31

MACD cross—

Stoch %K / %D2 / 22

ADX (14)23

+DI / −DI18 / 32

RSI divergence—

MACD divergence—

ATR %5.70%

ADR %4.43%

52w high29.83

52w low10.16

From 52w high-25.06%

Above 52w low+120.09%

New 52w highNo

SqueezeOff

Bollinger width26.22%

%B0.02

Donchian pos1.82%

Donchian high29.11

Donchian low22.23

AVWAP (52w high)25.97

vs AVWAP high-13.93%

AVWAP (52w low)21.06

vs AVWAP low+6.13%

OBV trendDown

Chaikin MF (20)-0.27

Today vs 20d3.95×

Avg vol (14d)1.48M

Avg vol (20d)1.3M

Avg $ vol (20d)32.19M

Market cap2.54B

RS Rating96 / 99

RS 3m (vs SPY)+10.71%

RS 6m (vs SPY)-6.72%

RS line new highNo

Trend template5/8

Technical rank37.4

1 week-6.60%

1 month-23.94%

3 months+15.21%

6 months+10.10%

1 year+111.65%

YTD+7.35%

P/E-11.95

P/B4.83

P/S365.72

P/FCF-12.65

EPS-2.43

Div yield—

ROE-40.45%

ROA-37.57%

Debt/Eq0.00

Current15.08

EV/EBITDA-10.47

Gross margin—

Net margin—

Rev growth-23.23%

EPS growth27.50%

Price target36.50

Target upside63.31%

Analyst ratingBuy

Institutional109.40%

Ent. value2.32B

Revenue0

Net income-73.13M

Gross profit—

Free cash flow-200.6M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out113.25M

Employees177

ListedFri, Oct 2, 2020

Free float77.44M

Float %84.4%

Short interest15.63M

Days to cover12.6d

Short volume64.1%

Squeeze score96 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.65 vs −$0.51

Last surprise-27.4% miss

Setup gradeA

Conviction77 / 100

Pattern quality—

Tech rank37.4 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance29.89

Support22.74

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in IMNM

All disclosures →

No recent disclosed trades by Congress in IMNM. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in IMNM · open-market 6 sells

Insider	Side	Shares	Value	Traded	Filed
Higgins Jack Chief Scientific Officer · Common Stock · 2026-09-11	Sell	13.2K	$334K	2026-09-11	2026-09-15
Higgins Jack Chief Scientific Officer · Employee Stock Option (right to buy) · 2026-09-11	Exercise	18K	—	2026-09-11	2026-09-15
Higgins Jack Chief Scientific Officer · Common Stock · 2026-09-11	Exercise	18K	$24K	2026-09-11	2026-09-15
Higgins Jack Chief Scientific Officer · Common Stock · 2026-09-11	Gift	8.8K	—	2026-09-11	2026-09-15
Barchas Isaac Director · Common Stock · 2026-08-12	Sell	11.05K	$301K	2026-08-12	2026-08-12
Barchas Isaac Director · Common Stock · 2026-08-11	Sell	62.29K	$1.6M	2026-08-11	2026-08-12
Barchas Isaac Director · Common Stock · 2026-08-10	Sell	10.13K	$264K	2026-08-10	2026-08-12
Barchas Isaac Director · Common Stock · 2026-08-07	Sell	15.25K	$397K	2026-08-07	2026-08-10
Barchas Isaac Director · Common Stock · 2026-08-06	Sell	20.84K	$543K	2026-08-06	2026-08-10
Rosett Max Chief Financial Officer · Employee Stock Option (right to buy) · 2026-07-23	Grant	94.5K	—	2026-07-23	2026-07-27

SEC filings

EDGAR filings in IMNM · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.